This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $546.27, moving +1.17% from the previous trading session.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
by Zacks Equity Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $517.83, moving +1.8% from the previous trading session.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $520.29, marking a -1.03% move from the previous day.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $541.28 in the latest trading session, marking a -1.94% move from the prior day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $551.72, marking a +1.21% move from the previous day.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $550.75, marking a +1% move from the previous day.
Here is What to Know Beyond Why Thermo Fisher Scientific Inc. (TMO) is a Trending Stock
by Zacks Equity Research
Thermo Fisher (TMO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing
by Zacks Equity Research
Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
Is Trending Stock Thermo Fisher Scientific Inc. (TMO) a Buy Now?
by Zacks Equity Research
Thermo Fisher (TMO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Thermo Fisher (TMO) Debuts Assay for Research on HIV Strains
by Zacks Equity Research
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
Is Most-Watched Stock Thermo Fisher Scientific Inc. (TMO) Worth Betting on Now?
by Zacks Equity Research
Thermo Fisher (TMO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
If You Invested $1000 in Thermo Fisher Scientific 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Top Research Reports for Amazon.com, Berkshire Hathaway & Thermo Fisher
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Berkshire Hathaway Inc. (BRK.B) and Thermo Fisher Scientific Inc. (TMO).
Take the Zacks Approach to Beat the Market: BMI, UI, ADP, CHRW in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Thermo Fisher (TMO) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Specialty Diagnostics segment revenues is disappointing.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 11.99% and 11.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks to Watch for Earnings on Jul 28
by Zacks Equity Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, TMO and BIO will likely fare this time.
Is a Surprise Coming for Thermo Fisher (TMO) This Earnings Season?
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.